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Glioblastoma and Clinical
Translation
The clinical outcomes and 5-year survival rate for patients
with glioblastoma (GB) make it among the most pernicious
and challenging diseases to treat. Despite all the resources,
time, and talent focused on developing targeted and/or lo-
cal delivery technologies by the biomaterials community for
GB, the clinical performance of the FDA-approved ther-
apy (BCNU-loaded polyanhydride wafers) and clinical tri-
als of other material approaches have been discouraging. As
disappointing is the remarkably stagnant clinical translation
of next-generation material approaches for GB. Despite en-
couraging pre-clinical results from hydrogels and modified
wafer formulations loaded with more efficacious chemother-
apies, a total of zero have completed even a phase I clinical
trial. Other strategies, including convection-enhanced deliv-
ery, microsphere formulations, or drug-loaded nanoparticles
have seen limited, albeit some, translation into the clinic with
mixed results. This lackluster progress can be attributed, in
part, to the paucity of communication between material sci-
entists, biomedical scientists, and clinicians. When exam-
ining the purported clinical relevance of embedding certain
material properties into formulations, it is clear that some
widely-known truths about the nature of GB progression
among clinicians have not reached the biomaterials commu-
nity.
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Furthermore, a closer examination of the lessons from
the BCNU wafers and other clinical trials of GB drug deliv-
ery materials may enrich and inspire materials scientists to
create new systems that satisfy unmet medical needs iden-
tified by the clinical community. In tandem, clinicians and
biomedical scientists may benefit from a short review high-
lighting the biocompatibility, safety, longevity, kinetics, tun-
ability, and efficacy of promising new drug delivery materi-
als without inundation by chemical and physical characteri-
zations or discussions.
Another key challenge in treating GB is an incomplete
understanding of disease pathophysiology, such as mech-
anisms driving intrinsic and adaptive GB cell chemoresis-
tance. A combined approach where biomedical scientists
and material scientists work in parallel and in close com-
munication with clinicians will be key for the timely devel-
opment of optimal therapeutic options.
Principles of Cancer Treatment
Following a landmark phase III trial in 2005, the Stupp
protocol was adopted as the standard of care for newly di-
agnosed GB: maximal safe surgical excision of the tumor
mass, followed by radiotherapy and concomitant temozo-
lamide (TMZ), followed by adjuvant TMZ.[1] Despite the
added ∼2.5 months survival afforded by the addition of
TMZ, the 5-year survival rate[2] remains poor at 5%. A num-
ber of factors make GB difficult to treat: (1) the high prolif-
erative and infiltrative capacity, heterogeneity, and intrinsic
and acquired chemoresistance of neoplastic cells; (2) the tu-
mor microenvironment; for example, the ability to induce
anergic states in surrounding lymphocytes and glial cells, re-
stricting the anti-tumor immune response; and (3) the brain
macroenvironment; namely the surrounding blood-brain bar-
rier and blood-tumor barrier restrict the ability of drugs to
reach the brain parenchyma.[3] Despite these unique chal-
lenges, the goal of adjuvant oncological therapy (whether
local or systemic) remains constant: maximizing cytotoxi-
city and reducing the risk of recurrence, whilst minimizing
associated toxicity and the emergence of resistance. Indeed,
the FDA-approved BCNU wafer technology was developed
with these needs in mind. By delivering chemotherapy di-
rectly into the tumor cavity, the restrictions imposed by the
blood-brain barrier are circumvented, and higher local drug
concentrations can be achieved with limited systemic toxic-
ity. However, drawing on general pharmacodynamics prin-
ciples, are BCNU wafers optimally designed to meet these
targets?
Based on in vitro colony-forming inhibition studies, the
cytotoxic actions of antitumor agents are, somewhat impre-
cisely, classified as time-dependent (cell cycle phase-specific
agents) or concentration-dependent (cell cycle non-phase-
specific agents).[4] This categorization has proved useful
when designing clinical dosing regimens for systemically
administered agents. In the case of TMZ, peak concentra-
tion, rather than prolonged exposure is thought to be more
important for treatment efficacy, consistent with its cell cy-
cle non-phase-specific mode of action.[5,6] Accordingly, a
dose-dense TMZ schedule (days 1 through 21 of a 28-day
cycle) does not improve survival in patients with newly di-
agnosed GB, compared to standard adjuvant treatment (days
1 through 5 of a 28-day cycle).[6] This logic should hold
for BCNU wafers. Given the cell cycle non-phase spe-
cific (and therefore concentration-dependent) mode of ac-
tion of BCNU, maximal anti-tumor effect should depend
on peak cytotoxic drug level rather than duration of expo-
sure. Accordingly, the FDA-approved wafers achieve high
initial dose-delivery of BCNU, which rapidly declines af-
ter 5-7 days.[7–10] Critically, however, systemic TMZ is ad-
ministered repeatedly, as six 5-day 4-weekly cycles, and
not as a single 5-day cycle (effectively equivalent to the
BCNU wafers). Indeed, increasing the number of adju-
vant TMZ cycles from 6 to 12 improves overall survival
by 8.4 months.[11] This therapeutic benefit may be mediated
by both increased cytotoxicity, triggered by increased TMZ-
mediated DNA alkylation, and minimization of acquired re-
sistance driven by sub-optimal drug exposure.[12] This key
lesson has been lost with the shift in focus from systemic to
locally-administered chemotherapy. The anti-tumor effect of
any chemotherapeutic agent, regardless of route of adminis-
tration, is time-critical: contingent on duration of exposure
for time-dependent agents, and repeated high-dose exposure
over time for concentration-dependent agents.
Optimizing chemotherapy dosing regimens also depends
on the trade-off between increasing drug dose/exposure to
enhance anti-tumor activity and minimizing concomitant
toxicity. The extended 12-cycle TMZ regimen may improve
survival relative to 6 cycles, but at the expense of increased
haematological toxicity.[11] Indeed, the minimum survival
threshold at which patients accept chemotherapy closely re-
lates to the severity of its toxic side effects.[13] Reason-
ably, this principle was not prioritized in the development
of the BCNU wafers, given that local delivery of BCNU cir-
cumvents the problem of high toxicity associated with sys-
temic administration.[14,15] BCNU wafers seems to be asso-
ciated with a number of local adverse events (namely cere-
bral oedema, intracranial infection, and pericavity necro-
sis), more than those expected from resection alone.[16–19]
Side-effects peak in the weeks/months following implanta-
tion, and can persists for up to 6 months.[17,19,20] Interest-
ingly, this more closely corresponds to the time-scale of
polymer degradation than the release kinetics of BCNU, sug-
gesting that these side-effects are more closely related to
persistence of the wafer within the resection cavity than to
early BCNU release.[7–10] In light of this, it is perhaps un-
surprising that phase III trials comparing BCNU to placebo
wafer have reported similar rates of adverse effects.[21] Af-
ter FDA-approval of the BCNU wafers, and with treatment
extended to patients who were not eligible in the initial clin-
ical trials, mounting concerns were reported through case re-
ports/series, and these may more closely reflect the compar-
ison of wafer to standard resection.[22]
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Two chemotherapeutic principles, the importance of sus-
tained/frequent drug exposure and the efficacy vs toxicity
trade-off, were perhaps too readily dismissed in the move
from systemic to local chemotherapy delivery. Immediately
post-implant, BCNU is rapidly released from the wafer, in
a ‘1-cycle’ fashion: the wafer delivers the majority of its
chemo-payload in under 1 week.[9,10,22] This explains, in
part, why the efficacy of BCNU wafers has been modest at
best. Subsequently, the empty wafer persists in the resec-
tion cavity, heightening adverse effects without concomitant
clinical benefit.
Notably, whilst cyclic dosing may translate into clini-
cal dividends in some patients, lack of a widely efficacious
chemotherapeutic agent remains an issue. Namely, patients
with unmethylated MGMT promoter GMs respond poorly
to treatment with DNA alkylating agents such as TMZ[23]
and BCNU;[24] among patients with methylated MGMT pro-
moter GMs, the addition of TMZ to radiotherapy confers
significant survival benefit (∼6.4 months) which is minimal
(∼0.9 months) among patients lacking methylation of the
MGMT promoter.[23] Once-susceptible GM cells can also
acquire resistance to TMZ following repeated exposure to
the drug via mechanisms including up-regulation of MGMT
levels and down-regulation of DNA mismatch-repair pro-
teins.[25] Overcoming this challenge will require that materi-
als science research advance in tandem and in close collabo-
ration with drug discovery, which is informed by biomedical
scientists and their mechanistic insights into GM pathophys-
iology.
Outcomes and Lessons from the
Clinic
While the clinical benefits of BCNU wafers have not greatly
ameliorated the tumor burden in GB patients,[26] an abun-
dance of clinical literature using this adjuvant therapy pro-
vides key and quantitative lessons for the next generation of
local chemotherapy delivery systems. In the development
of the underlying material of the wafer technology, a moti-
vational principle was the sustained local delivery of a high
chemotherapy concentration within the pharmaceutical win-
dow as an adjuvant therapy.[27–30] The distinct time scales
of drug release and material longevity in vivo are among the
most critical factors involved in developing, optimizing, and
evaluating drug delivery technology and have not been given
the attention they deserve. Furthermore, a key lesson from
the clinic is that the increase to an extended 12-cycle TMZ
regimen may provide benefit in reducing tumor burden and
prolonging survival.
Key lessons:
(a) Increasing the number of adjuvant systemic TMZ cycles
confers a survival benefit, at the cost of heightened side-
effects
Figure 1 Graphical illustration of concentration, efficacy, and tox-
icity profiles of an idealized drug delivery system against systemic
TMZ adjuvant therapy (Stupp protocol) and stiff FDA-approved
BCNU wafers. (a) limitations in systemic toxicity of TMZ are over-
come with local delivery. An ideal delivery system will possess a
mitigated bolus and 0th or 1st order release kinetics. (b) Achieve-
ment of a high local concentration of TMZ in local delivery systems
sustained over many weeks produces a reduction in tumour burden
and increase in efficacy in the idealized local delivery systems. (c)
BCNU wafers’ stiffness mismatch with tissue contribute to toxicity
and negative side-effects after >80% of drug release. A soft ide-
alized local drug delivery system will have minimal acute toxicity
and no negative chronic immune response.
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(b) BCNU wafers release the majority of drug payload in the
first week, and the side effects of this technology begin after
this massive initial bolus release
(c) A higher stiffness matrix does not automatically equate
to prolonged release in vivo, and importantly the higher stiff-
ness may exacerbate the negative side effects
Critical materials challenges and unmet medical needs:
(a) local delivery whose time scale for drug release is on par
with the time scale for matrix degradation
(b) materials capable of eluting a prolonged 0 or 1st order
release of drug on time scales of months rather than days
(c) achieving such pharmacokinetic properties with a
degradable, soft material
In summary, BCNU wafers are too stiff[31,32] and remain
too long in the body for the therapeutic benefit they provide
novel methods for local chemotherapy emerging from the
biomaterials community should be considered. We hypoth-
esize that improved efficacy and reduced toxicity may de-
pend on, at minimum, providing the same bolus release of
chemotherapy from a softer material that biodegrades much
faster than the wafer technology. Further benefit, albeit a
more technologically challenging solution, may be realized
by developing a degradable soft material that remains in the
body on the order of 6-12 months while simultaneously elut-
ing chemotherapy with 0th or 1st order release kinetics for
the same duration.
Promising Soft Materials for Local
Delivery
There is mounting evidence from the biomaterials com-
munity that existing hydrogel technology can capture the
value of a wafer-type local therapy while mitigating neg-
ative side effects, putting them at the forefront of promis-
ing local chemotherapy delivery systems in GB. Recent re-
views have summarized some of the literature on these local
drug delivery hydrogels.[32,33] Certain systems are particu-
larly promising, or have developed proof-of-concept princi-
ples that should be adopted with any clinical therapy.
Degradable, soft hydrogels, which are distinct from clas-
sic non-degradable materials such as polyHEMA hydrogels,
have a number of advantages compared to BCNU wafers. As
discussed, wafers elute the vast majority of their chemother-
apy payload in 1 week, but the remaining empty wafer may
increase the risk of local adverse effects. Critically, hydro-
gels can be tuned to degrade under different time-scales and
are generally bio-degraded in under 1 month. Although the
kinetics of chemotherapy release may be comparable, hy-
drogels do not last long enough in the resection cavity (nor
are stiff enough) to cause the same adverse effects as wafers.
Promising examples of rapidly bio-degradable hydrogels in-
clude supramolecular or physically assembled hydrogels for
parenteral drug delivery applications.[32,34–36] For example,
we previously reported physical hydrogels for local GB drug
delivery that self-assemble via host-guest interactions.[31,37]
These materials release drugs with a bolus, just as the BCNU
wafers do, but are biodegradable under timescales of days to
weeks. These materials confer an additional advantage over
wafers: because their intended use is in less-invasive par-
enteral drug delivery, materials scientists often embed shear-
thinning properties into these supramolecular hydrogels so
that they can be non-surgically implanted in vivo and quickly
recover their original stiffness. Stiff BCNU wafers do not
possess these shear-thinning and recovery properties. This
injectability is advantageous for GB drug delivery because
as the material recovers, it fills the gap of the resected tu-
mor with superior epitaxial engagement.[31,32] Pre-clinical
data suggest this improvement in bioavailability affords clear
therapeutic benefit,[31] which may mean that shear-thinning
soft materials, whilst retaining the bolus release kinetics of
the wafer technology, are more efficacious than their stiff
counterparts.
However, if local drug delivery for GB is to move away
from this wafer paradigm of 1-cycle benefit, and adopt the
more beneficial pharmacokinetic profile from systemic ther-
apy, which includes repeated cycles of TMZ over the course
of several months, then the local drug delivery material can-
not degrade in under 1 month, as is the case with degrad-
able, physical hydrogels. Furthermore, the local therapy can-
not elute most of its payload in under 1 month, as is the
case with both physical hydrogels and the BCNU wafers.
To avoid the side-effects of the wafer, the local drug deliv-
ery adjuvant should also be soft with a stiffness on par with
that of tissue. This is no easy task: it is highly challeng-
ing to develop a physical hydrogel which is biocompatible,
biodegradable, injectable, soft and has an in vivo duration
greater than 1 month. This particularly burdensome engi-
neering challenge will require new and creative solutions in
chemistry and materials science.
Of course, developing long-lasting, soft, and degradable
materials for GB delivery is only useful if the timescale of
drug elution is also on the order of 6 to 12 months. As pre-
viously discussed, most supramolecular hydrogels and the
FDA-approved wafers possess a bolus release profile. Many
approaches have been reported in the literature to mitigate
a bolus release, including using capsules or nanoparticles
to retard the drug release by introducing an upstream rate-
limiting step.[38–40] Ranganath and colleagues demonstrated
the utility of PLGA nanocarriers in providing sustained drug
release and greater engineering control over the release ki-
netics for a GB target.[38,39] Rahman and colleagues ex-
plored the utility of an interesting PLGA/PEG microparticle-
based paste as a local adjuvant therapy.[41] Such an approach
is potentially advantageous in particular for selective tuning
of release kinetics for combination therapies, i.e. chang-
ing the release rate of one drug (e.g. hydrophobic small
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molecule) without disturbing the release rate of a second
loaded drug (e.g. protein).
Other approaches include exploiting lipid carriers.[42–45]
These strategies are promising in providing a scalable
method of reducing a bolus release of drugs; in particular,
their utility in controlling the release kinetics and improv-
ing stability of hydrophobic small molecule drugs[46] is es-
pecially useful in anticancer therapy. The delivery of hy-
drophobic drugs is an important[47] and active area of re-
search, and such lipid carriers are promising both for deliv-
ery of these poorly-soluble drugs and combination therapies
with proteins.
The field has begun to turn to hydrophobic moieties not
just for controlled elution of a therapeutically relevant con-
centration of hydrophobic small molecules, but as a means
of overcoming the fundamental mass transfer limitations in
controlled drug delivery using a water-based material. Soft
materials that serve as alternatives to supramolecular hydro-
gels include systems such as oleogels.[48] These nonaqueous
gels have seen virtually no translation into GB local thera-
peutics, but a new generation of solvent-free, soft biomate-
rials for drug delivery are emerging, including supramolecu-
lar poly(caprolactone)/poly(ethylene glycol) block polymer
systems[36] developed by Wang and colleagues. Hydropho-
bic solvent-free gels are promising because the absence of
bulk solvent may prolong their release kinetics in vivo.
Conclusions
In summary, results from the clinic provide useful quantita-
tive lessons and benchmarks to guide the biomaterials com-
munity in developing novel local chemotherapy delivery sys-
tems. The clinical success of a higher number of adjuvant
systemic TMZ cycles should guide the adoption of similar
time scales and release kinetics in local drug delivery mate-
rials. The stiffness mismatch of BCNU wafers informs the
mechanical properties that ideal systems will have.
Many promising soft materials for local drug delivery are
in development but have seen little clinical translation. It
would be advantageous for physicians to explore such sys-
tems utility as adjuvant therapies. These materials are im-
mediately available and have strong potential to both miti-
gate negative side effects incurred from BCNU wafers and
provide a more efficacious bolus release due to superior epi-
taxial engagement.
Unmet medical needs remain, and biodegradable soft
materials that have extended durations in vivo and elute
chemotherapy for similar time scales of many months
may very elegantly satisfy these needs. Transdisciplinary
communication between clinicians, material scientists, and
biomedical scientists is needed for the clinical translation of
novel therapies that satisfy such engineering requirements.
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